🔎 Trials Near Me

Home › Migraine › Maryland

Migraine clinical trials in Maryland

7 studies for Migraine are looking for participants at sites in Maryland.

Cities in Maryland

NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder

  • National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 8 to 70 · All sexes · Updated Oct 2, 2026 · NCT05669703

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

  • Pharmasite Research, Inc. /ID# 227908, Baltimore
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Sep 14, 2026 · NCT05125302

Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine

  • Johns Hopkins Medicine, Baltimore
Recruiting
Ages 18 to 80 · All sexes · Updated Sep 3, 2026 · NCT07223008

A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine

  • MedStar Health Research Institute, Olney
Recruiting
Ages 22 to 84 · All sexes · Updated Aug 28, 2026 · NCT07719608

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  • Headlands Research - PharmaSite, Pikesville
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 20, 2026 · NCT07645924

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

  • University of Maryland School of Medicine, Baltimore
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Jun 12, 2026 · NCT05164172

Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents

  • National Intrepid Center of Excellence (NICOE), Bethesda
RecruitingObservational study
Ages 18 and older · All sexes · Updated Dec 5, 2025 · NCT07267819

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.